Latest / Stuff You Should Know / How Gene Patents Work

Transcript

How Gene Patents Work · Stuff You Should Know

• 0:00
  Speaker 1: Brought to you by the reinvented two thousand twelve camera.
• 0:03
  Speaker 1: It's ready. Are you welcome to stuff you should know
• 0:08
  Speaker 1: from House toff works dot Com. Hey, and welcome to
• 0:16
  Speaker 1: the podcast. I'm Josh Clark. There's Charles W. Chuck Bryant.
• 0:21
  Speaker 1: This is William Shatner. You have the sound of a
• 0:26
  Speaker 1: man who sounds like he's leaving town. I do. It
• 0:32
  Speaker 1: is a weekend. Yeah, I'm leaving town too. Nice are
• 0:35
  Speaker 1: you going? I'm going to see my sister and my
• 0:38
  Speaker 1: two nieces. My brother in law is not there, but
• 0:41
  Speaker 1: in Jacksonville, North Carolina. Very nice at the U. S.
• 0:45
  Speaker 1: Marine Corps bas very nice. You're gonna go to the
• 0:49
  Speaker 1: p X Campbell of June. I think, uh, sure, I'll
• 0:53
  Speaker 1: go to the p X. Should get some stuff there.
• 0:55
  Speaker 1: It's all like in a military discount some TAMO and
• 0:58
  Speaker 1: m O. Just walk like you're supposed to be in there,
• 1:02
  Speaker 1: you know, maybe make eye contact with everybody, try to
• 1:04
  Speaker 1: wither him and they'll be like, oh, he's a soldier.
• 1:07
  Speaker 1: I always stand out like a swart thomb on the
• 1:10
  Speaker 1: military basis. You're like, this is a fat, hairy guy. Yeah,
• 1:15
  Speaker 1: why is he here? And should I kill him, So
• 1:18
  Speaker 1: you're excited. Yeah, I haven't seen my sister in a while.
• 1:20
  Speaker 1: What about you? What you got going on? Uh? We
• 1:23
  Speaker 1: are going to New York, you me and I. Um
• 1:25
  Speaker 1: for friends wedding. Two friends wedding, two male friends wedding. Yeah,
• 1:31
  Speaker 1: awesome and it's official now. Congratulations to those guys. Yeah,
• 1:35
  Speaker 1: Mitch and Patrick, who are friends on the Facebook page,
• 1:38
  Speaker 1: tried to help them out. They were like in a
• 1:41
  Speaker 1: contest for crighton barrel wedding two steaks. Yeah, and a
• 1:45
  Speaker 1: lot of people showed up and bumped them from like
• 1:47
  Speaker 1: number twenty something. They're like number one for a little
• 1:50
  Speaker 1: while and then they just got crushed. So hats off
• 1:53
  Speaker 1: to everybody on our Facebook page who helped them out.
• 1:55
  Speaker 1: They are very grateful and to them. Yes me, best
• 2:00
  Speaker 1: wishes from stuff you should know from Mitch Patrick. Absolutely. Okay,
• 2:04
  Speaker 1: So Chuck, you want to get down to this, Yes,
• 2:06
  Speaker 1: how Jeane Simmons works Origen shall it Jene Cisco Gene
• 2:15
  Speaker 1: croupa well and with gene Gene pattents really is what
• 2:19
  Speaker 1: we're talking about, right, So it's interesting, I have I agree,
• 2:24
  Speaker 1: interesting and terrifying. Um. And by the way, I just
• 2:28
  Speaker 1: want to go ahead and say that there is a
• 2:30
  Speaker 1: documentary companion documentary that's required viewing for this one. It's
• 2:34
  Speaker 1: called The Corporation. Uh, if you have Netflix, it's streaming
• 2:38
  Speaker 1: on Netflix. You can also order the DVD or whatever.
• 2:42
  Speaker 1: But you could watch it literally right the second. It's
• 2:44
  Speaker 1: probably all over YouTube too. It's like one of those docs,
• 2:47
  Speaker 1: very well made, good stuff. It touches on a lot
• 2:50
  Speaker 1: of stuff in here and just goes into greater depth.
• 2:53
  Speaker 1: So I say, check out The Corporation. It's a good
• 2:55
  Speaker 1: documentary either way. Um. But uh, let me let me
• 3:00
  Speaker 1: give you a little story here. There is a condition.
• 3:04
  Speaker 1: It can be congenital. It can actually be acquired strangely enough,
• 3:07
  Speaker 1: although I didn't find out how. But it's called UM
• 3:11
  Speaker 1: growth hormone deficiency, right, okay, And basically it just means
• 3:15
  Speaker 1: that you are short, you're smaller in stature UM then
• 3:20
  Speaker 1: is average. Maybe you're smaller than the rest of your
• 3:24
  Speaker 1: family members, who knows, but the the point is that
• 3:27
  Speaker 1: your pituitary glands aren't producing enough growth hormone. Like manuel Lewis,
• 3:33
  Speaker 1: I imagine that he has some sort of growth hormone deficiency.
• 3:36
  Speaker 1: I think it's an umbrella term, but yes, UM, the
• 3:40
  Speaker 1: good thing is that it's treatable, and it's been treatable
• 3:42
  Speaker 1: for a while. And we knew for a very long
• 3:44
  Speaker 1: time where to get the treatment, where to get human
• 3:47
  Speaker 1: growth hormone, and that was extracting it from the pituitary
• 3:51
  Speaker 1: glands of cadavers. Up until the seventies, if you had
• 3:56
  Speaker 1: growth hormone deficiency and you were given injections, the stuff
• 3:59
  Speaker 1: they were in acting you with was extracted from cadaver's
• 4:02
  Speaker 1: pituitary glands. But it was still good to go. It was.
• 4:06
  Speaker 1: It worked, yeah, um, but it was very very expensive.
• 4:10
  Speaker 1: I mean, the extraction process, getting your hands on a
• 4:13
  Speaker 1: dead body. I mean, there's a lot of factors involved. Uh.
• 4:16
  Speaker 1: And then in in the until the nineteen eighties when
• 4:20
  Speaker 1: a company called Novo Nordisk got a patent for a
• 4:23
  Speaker 1: product called nano nanor one nano one. Yeah, it's just
• 4:28
  Speaker 1: a mouthful that it had created in the nineteen seventy three,
• 4:31
  Speaker 1: but it didn't get a patent until nineteen two. Couldn't
• 4:33
  Speaker 1: they just call it go juice? Yeah, you know, or
• 4:36
  Speaker 1: grow juice that be that would be much more appropriate, right, Okay,
• 4:41
  Speaker 1: we'll figure that out later. So the history to me
• 4:43
  Speaker 1: it was is one of the most interesting parts here.
• 4:45
  Speaker 1: And we'll get to nineteen eight two, which was a
• 4:47
  Speaker 1: landmark here in this field. But let's back up, Josh, Yes,
• 4:51
  Speaker 1: let's use the way back machine because we haven't done that. Now,
• 4:55
  Speaker 1: there's a cob women here there. It's musty. Uh. He's
• 5:00
  Speaker 1: been eating cheese too. You know. There's like rappers here
• 5:03
  Speaker 1: process cheese. Interesting. Uh, So let's go back in time.
• 5:06
  Speaker 1: There were three three rulings over the years, starting in
• 5:10
  Speaker 1: eighteen fifty three that sort of lead to what we're
• 5:12
  Speaker 1: talking about, but they weren't consistent. They sort of flip
• 5:15
  Speaker 1: flopped on the subject. Uh. In eighteen fifty three, Robert
• 5:18
  Speaker 1: Morse of the Telegraph fame was initially denied his patent
• 5:23
  Speaker 1: because part of it involved electromagnetism, a key part of it,
• 5:27
  Speaker 1: and they said he can't fatten electromagnetism. No, why, silly boy,
• 5:32
  Speaker 1: Because it's a principle of nature. Right. It's like, uh,
• 5:36
  Speaker 1: my device uses that cloud right there, so I'm gonna
• 5:38
  Speaker 1: patent that cloud. Like you can't patent a cloud. Well,
• 5:42
  Speaker 1: what about the process that makes clouds? No, you can't.
• 5:44
  Speaker 1: It's nature, that's natural. You can't patent nature. And this
• 5:48
  Speaker 1: is back when the U. S. Patent Office was the
• 5:51
  Speaker 1: god fearing US Patent Office and they knew what to
• 5:53
  Speaker 1: issue patents for and whatnot to not the crazy cuckoo
• 5:57
  Speaker 1: mixed up patent office of today. That's right where you
• 6:01
  Speaker 1: can patent thoughts and dreams. I'm patenting you chuck actually
• 6:06
  Speaker 1: on that already and you owe me to indollars for
• 6:09
  Speaker 1: you and saying that, uh so. Following that the second
• 6:14
  Speaker 1: ruling in nineteen twelve, another court ruled that you could
• 6:19
  Speaker 1: patent adrenaline because it's a distilled type of adrenaline that
• 6:23
  Speaker 1: was treated in a lab outside the body and it
• 6:26
  Speaker 1: was different than the natural adrenaline inside the body. Then,
• 6:29
  Speaker 1: after World War Two, another ruling reversed it again in
• 6:33
  Speaker 1: the Supreme Supreme Court said, I'm sorry, you cannot patent
• 6:37
  Speaker 1: this mixture of bacteria that you're making in your lab
• 6:42
  Speaker 1: right even doesn't exist in nature. And this would later
• 6:46
  Speaker 1: become a real touchstone in this argument, like does this
• 6:49
  Speaker 1: exist in nature? Like that cloud right there? Uh you,
• 6:53
  Speaker 1: it's natural. You can't patent it, But could you patent
• 6:57
  Speaker 1: a process or a cloud that you could create in
• 7:00
  Speaker 1: the lab that nature doesn't produce? Him? Maybe isn't capable
• 7:03
  Speaker 1: of producing. That's where it gets Harry. Yeah. Another big
• 7:06
  Speaker 1: step forward was the Plant Patent Act of nineteen thirty
• 7:10
  Speaker 1: thanks to a dude to name Luther Burbank, which is
• 7:14
  Speaker 1: a pretty rocking name. I think that's my new hotel name,
• 7:18
  Speaker 1: Luther Burbank. It's pretty cool for a you know, early
• 7:22
  Speaker 1: twentieth century white dude. Uh. He was a botanist and
• 7:25
  Speaker 1: he created more than eight hundred strains and varieties of plants,
• 7:29
  Speaker 1: including the Shasta daisy, the fire poppy, and the white BlackBerry.
• 7:34
  Speaker 1: I'm a fan of the Shasta daisy. Yeah. Yeah, Well
• 7:37
  Speaker 1: you have Luther Burbank. Thank I see him wearing four
• 7:40
  Speaker 1: finger rings, that says luth Yeah. Uh so he was obviously,
• 7:47
  Speaker 1: uh you know, pretty inspired to create plants. And they said,
• 7:51
  Speaker 1: you know what, that's pretty neto that you can do
• 7:53
  Speaker 1: all this stuff, so you should be allowed to We're
• 7:55
  Speaker 1: gonna pass this Plant Act. But don't even try two
• 8:00
  Speaker 1: patent bacteria again. There's a problem with bacteria that the
• 8:05
  Speaker 1: court has always traditionally disallowed. Apparently they consider bacteria more
• 8:11
  Speaker 1: natural life than a hybrid plant. It's true because of
• 8:15
  Speaker 1: the next case and that plant, that plant patent act um. Really,
• 8:20
  Speaker 1: that's that is a big deal, even just beyond like
• 8:23
  Speaker 1: what we're talking about, and we'll get to that later,
• 8:25
  Speaker 1: like what effects that that has had? Yeah? Um. And
• 8:30
  Speaker 1: then there's also a Plant Protection Act of nineteen seventy
• 8:34
  Speaker 1: that also allowed patents as well, but again this allowed bacteria.
• 8:38
  Speaker 1: Bacteria keeps getting kicked around, kicked around, kicked around until right,
• 8:45
  Speaker 1: was that a Diamond v. Chakrabarty. Yes, Ananda Chakrabarty worked
• 8:51
  Speaker 1: for GE developed a bacterium that could break down crude
• 8:55
  Speaker 1: oil and said, hey, we should use this for oil spills.
• 8:57
  Speaker 1: Very useful, great idea. Uh, the Court of Customs and
• 9:01
  Speaker 1: Patent Appeals, I'm sorry, it was initially rejected. And then
• 9:07
  Speaker 1: the Customs and Patent Appeals office overturned that, saying that
• 9:12
  Speaker 1: the fact that it's alive has no significant purpose in
• 9:14
  Speaker 1: our patent office. Right. And also you left out that
• 9:18
  Speaker 1: that chucker body um created a bacteria that didn't exist
• 9:22
  Speaker 1: in nature. Oh, it was. It was brand new, it
• 9:24
  Speaker 1: was recombinant. He made it himself. That's pretty cool, yes,
• 9:28
  Speaker 1: but then the bacteria. Uh. The Supreme Court then argued
• 9:32
  Speaker 1: the case and in nineteen eighty Warren Burger wrote that
• 9:36
  Speaker 1: whoever invents, and this is very key moving forward, whoever
• 9:39
  Speaker 1: invents or discovers any new and useful process, machine, manufacturer,
• 9:43
  Speaker 1: or and this is the key, composition of matter or
• 9:47
  Speaker 1: any new and useful improvement thereof, may obtain a patent,
• 9:50
  Speaker 1: therefore subject to the blah blah blah blah blah if
• 9:54
  Speaker 1: some fact though, but composition matters the key three words there, Right,
• 9:59
  Speaker 1: There's a big difference between a product of nature or
• 10:01
  Speaker 1: a principle of nature and the composition of matter, which
• 10:05
  Speaker 1: could be anything from you know, using two types of
• 10:09
  Speaker 1: metal to create an alloy, or creating two types of
• 10:13
  Speaker 1: DNA to create yeah, something like insulin um. And by
• 10:16
  Speaker 1: the way, diamond and diamond v chakra body is diamond.
• 10:21
  Speaker 1: Was the the head of the patent's office. So when
• 10:24
  Speaker 1: you fought against it, yeah, he he sued him to
• 10:27
  Speaker 1: be like, no, yeah, this is this is wrong. When'd
• 10:29
  Speaker 1: you feel like you're in trouble if the if the
• 10:31
  Speaker 1: head of the patents office was suing you, like, it
• 10:35
  Speaker 1: just seems worse, you know. Buton and that changed everything.
• 10:39
  Speaker 1: Um within two years, the first patent for UM, the
• 10:43
  Speaker 1: first gene patent, what we would call a gene patent
• 10:46
  Speaker 1: UM was issued to the University of California. Yeah, for
• 10:51
  Speaker 1: UM a hormone engineered too. I guess for milk production,
• 11:00
  Speaker 1: I'm not sure. And it was involved in breast cancer treatment,
• 11:02
  Speaker 1: but I don't know exactly what it did. I got
• 11:04
  Speaker 1: you UM. And then the same year insulin was patented
• 11:09
  Speaker 1: We're comminentt insulin, which was huge also. So that was
• 11:12
  Speaker 1: the same year that Novo nor Disc got its patent
• 11:15
  Speaker 1: for um nannermant nan normandy, the human growth hormone product. Yeah,
• 11:24
  Speaker 1: so UM that really just kind of opened up the floodgate.
• 11:28
  Speaker 1: Chakra body changed everything, and that that shows up in
• 11:32
  Speaker 1: the corporation too. It's pretty interesting how they talked about
• 11:34
  Speaker 1: that UM and but really I guess as far as
• 11:40
  Speaker 1: gene patents go, the real moment when everything changed was
• 11:45
  Speaker 1: in the late nineties when this little known group at
• 11:48
  Speaker 1: the time popped up UH in the media and said, hey,
• 11:53
  Speaker 1: we're almost finished entirely mapping the human genome. And the
• 11:58
  Speaker 1: U S Patent Office workers went and there's a flood
• 12:04
  Speaker 1: of patent requests. Right, one was for Pandora radio. Wasn't
• 12:09
  Speaker 1: that based on that? The Music Genome project, what's it
• 12:12
  Speaker 1: I think so. I would imagine if that's what they
• 12:14
  Speaker 1: called it or inspired by it. UM. But yeah, everyone
• 12:18
  Speaker 1: lined up all the time. It's like, oh, pattent this patent.
• 12:20
  Speaker 1: That they'd be like, I heard about this GENO, want
• 12:22
  Speaker 1: to patent it. I want to pattent this one. And
• 12:24
  Speaker 1: so they were inundated with it. And so in two
• 12:26
  Speaker 1: thousand one, the US Patent and Trademark Office the US
• 12:29
  Speaker 1: p t O UM issued new guidelines saying, Okay, yes,
• 12:34
  Speaker 1: anybody can apply for a patent, but you have to
• 12:36
  Speaker 1: know what you're talking about. You have to know you
• 12:39
  Speaker 1: have to know what the gene does, or you have
• 12:41
  Speaker 1: to have come up with some process UM using this gene.
• 12:45
  Speaker 1: There's there's there. There has to be criteria everybody, everybody. Yeah,
• 12:49
  Speaker 1: there has to be criteria UM. And that definitely UM
• 12:54
  Speaker 1: allowed some of the high there was a high water
• 12:58
  Speaker 1: mark in the the tie ebbed a little bit, a
• 13:01
  Speaker 1: little bit. But currently I believe, which was the initial
• 13:06
  Speaker 1: stat there are three to five thousand human gene patents
• 13:12
  Speaker 1: right now in the US alone. Yeah, forty seven thousand
• 13:16
  Speaker 1: involving inventions like equipment involving genetic material or insulin is
• 13:23
  Speaker 1: another example. Yeah, that's an invention using genetic material. But
• 13:27
  Speaker 1: there are more than three million on file as applicants. Yeah,
• 13:31
  Speaker 1: like that impending shirt ye so um, and that's with
• 13:36
  Speaker 1: the the tide ebbing. I hope, I hope it's ebbing.
• 13:41
  Speaker 1: And just in the United States again, isn't it? Yeah,
• 13:44
  Speaker 1: in the United States, Um, and there's plenty in Europe
• 13:48
  Speaker 1: and Japan. It's basically Europe, Japan, and the US are
• 13:51
  Speaker 1: the leaders in issuing patents for this kind of stuff.
• 13:54
  Speaker 1: Like basically, if you want to push the rest of
• 13:57
  Speaker 1: the world around, you go get a patent at one
• 14:00
  Speaker 1: of one of these areas patent offices. So uh, well,
• 14:05
  Speaker 1: let's talk specifically about the US, right, Um, let's talk patents. Yeah,
• 14:09
  Speaker 1: if you want to get a patent, you have to
• 14:11
  Speaker 1: you have to meet some criteria. Um. It doesn't matter
• 14:15
  Speaker 1: what the patents for, whether it's for the dippie bird
• 14:17
  Speaker 1: or you know, for human growth hormone. Um. And so
• 14:22
  Speaker 1: for any any invention to get a patent to be
• 14:26
  Speaker 1: a proof for a patent, um it has to meet
• 14:28
  Speaker 1: for criteria. Right, has to be useful, it has to
• 14:31
  Speaker 1: be non obvious, right, Like it can't be a shoe string.
• 14:38
  Speaker 1: I don't know, I would have non what would an
• 14:41
  Speaker 1: obvious one be? A wonder an obvious invention would be
• 14:47
  Speaker 1: um man, I don't know. I'm just curious. Maybe using
• 14:51
  Speaker 1: peppermint too too, um fight bad breath? Maybe obvious. Yeah,
• 15:00
  Speaker 1: it's obvious. Anybody can do that. You can't patent that.
• 15:02
  Speaker 1: There you go, there's air non obvious example. Um. It
• 15:05
  Speaker 1: has to be novel, right, um. And it has to
• 15:09
  Speaker 1: meet the enablement criterion, which is a big deal. And
• 15:13
  Speaker 1: this is pretty much the whole reason patents exist. One
• 15:16
  Speaker 1: of the big reasons. It's got to have detail. It
• 15:18
  Speaker 1: can't be just a big, broad, esoteric thing. It's got
• 15:21
  Speaker 1: to be detailed enough where someone in that field can
• 15:25
  Speaker 1: figure it out and use it, right, And this is
• 15:27
  Speaker 1: this is one of the major reasons the patent office exists.
• 15:31
  Speaker 1: It's to say, Okay, thank you for sharing your findings
• 15:34
  Speaker 1: with the rest of the world. We're gonna give you
• 15:36
  Speaker 1: twenty years of exclusivity. But in return, you're you're being
• 15:41
  Speaker 1: totally transparent. Here's all of the processes, here's all the notes,
• 15:44
  Speaker 1: here's anything that anybody working in your field can can
• 15:48
  Speaker 1: look at and use to build upon your research, or
• 15:52
  Speaker 1: they pay you well, but can they get it and
• 15:55
  Speaker 1: change it enough to where it doesn't You can't. And
• 15:58
  Speaker 1: those are called patent trolls and a only they're a
• 16:00
  Speaker 1: big problem right now. They're they're towarding technology. I think
• 16:03
  Speaker 1: tech stuff did something on patent trolls recently. Interesting. Yeah. Um,
• 16:08
  Speaker 1: so you if you are issued a patent, you get
• 16:11
  Speaker 1: twenty years of exclusivity. Nobody can use it, uh um,
• 16:16
  Speaker 1: market it, sell it anything as you do with your
• 16:19
  Speaker 1: invention or process unless they pay you. They have to
• 16:22
  Speaker 1: go through you, and you license it and reap the benefits, right, Yeah.
• 16:25
  Speaker 1: And the reason it was such a mad rush when
• 16:27
  Speaker 1: the genome project was first completed because obviously the first
• 16:31
  Speaker 1: person to invent something gets the patent. So if you
• 16:34
  Speaker 1: can prove that, then that's yours for twenty years. So
• 16:37
  Speaker 1: well that's based on the first to invent principle. Yeah,
• 16:40
  Speaker 1: right exactly, So you have to prove that and then
• 16:42
  Speaker 1: after that you've got it for twenty years. And everyone
• 16:45
  Speaker 1: was in a big rush to be the first with
• 16:48
  Speaker 1: these gene patents. Have you heard the story of um
• 16:51
  Speaker 1: Alexander Graham Bell and Elijah what was his name? Do
• 16:56
  Speaker 1: you mean? The real guy? He would invented the telephone? Yeah,
• 16:59
  Speaker 1: what's his name? Oh? Was that the case? I knew
• 17:01
  Speaker 1: there was some stink there, but I wasn't sure. Um,
• 17:04
  Speaker 1: Elijah Gray. Apparently Elijah Gray invented a telephone that looked
• 17:09
  Speaker 1: and worked way way more like the ones we used today,
• 17:15
  Speaker 1: I should say, the ones we used in the used
• 17:17
  Speaker 1: in the seventies and eighties. Right. It wasn't stealth phone,
• 17:19
  Speaker 1: but you know, the kind of rotary dial all that. Um.
• 17:23
  Speaker 1: But Alexander Graham Bell beat him to the patent office
• 17:28
  Speaker 1: and um, now did he steal his ideas? Or was
• 17:30
  Speaker 1: it just confirms independent? Um? And I can't remember what
• 17:34
  Speaker 1: that's called. But there's there's there's an idea that, like
• 17:37
  Speaker 1: you know, oh the zeitgeist, we're all, you know, ideas
• 17:40
  Speaker 1: kind of float out there for anybody to latch onto,
• 17:43
  Speaker 1: and sometimes people do independently. I wonder how far apart
• 17:45
  Speaker 1: they were from each other and being completed, And like
• 17:49
  Speaker 1: I wonder if it was literally literally like my horse
• 17:51
  Speaker 1: fell sick that day and I couldn't make it to
• 17:53
  Speaker 1: the office. Um, but did I don't remember how how
• 17:56
  Speaker 1: close it was, but it was pretty close. Um. So Uh,
• 18:01
  Speaker 1: the Patent office has this first to invent principle where
• 18:04
  Speaker 1: it's not necessarily like who beat who to the patent office.
• 18:08
  Speaker 1: It's if you have a situation like that, who's been
• 18:11
  Speaker 1: working on this longer or who reached a landmark longer,
• 18:14
  Speaker 1: and then that's who gets the patent. That's why there
• 18:17
  Speaker 1: was like you said that mad rush, because you know,
• 18:21
  Speaker 1: it's like I noticed this first, so let me go
• 18:24
  Speaker 1: ahead and get my patent in well. And with the
• 18:26
  Speaker 1: case of like insulin or any of any of these
• 18:29
  Speaker 1: gene patents, really you can't just say like, oh, I
• 18:31
  Speaker 1: got this thing like you. They have to have it
• 18:33
  Speaker 1: on file, which is something I never knew. There are
• 18:36
  Speaker 1: twenty six culture depositories around the world thanks to and
• 18:41
  Speaker 1: this is such a mouthful, thanks to the Budapest Treaty
• 18:44
  Speaker 1: on the International Recognition of the deposit of Microorganisms for
• 18:48
  Speaker 1: the purpose of Patent Procedure. So basically, it's like a
• 18:52
  Speaker 1: repository where you send in your sample, right, and that
• 18:55
  Speaker 1: the way I understand it, um, And there's twenty six
• 18:58
  Speaker 1: of them worldwide, right, Yeah. And if it is a
• 19:03
  Speaker 1: a product of if it's something you remove from from
• 19:05
  Speaker 1: the body and processed, the patent only applies to the
• 19:09
  Speaker 1: very end result that you send in, not like the
• 19:12
  Speaker 1: little stages along the way, although you can patent that
• 19:16
  Speaker 1: those stages, Yeah, but they just have to be independent
• 19:18
  Speaker 1: of one another, right yeah, alright. So, um, you've you've
• 19:23
  Speaker 1: submitted your sample to a depository, you have applied for
• 19:27
  Speaker 1: the patent, it's been issued. You're good to go. Um,
• 19:33
  Speaker 1: what are you patenting? Right? Like, I think there's a
• 19:36
  Speaker 1: huge misunderstanding among the public that you're walking around and
• 19:43
  Speaker 1: the some company owns the the rights to your genes. True? False? False?
• 19:50
  Speaker 1: That is false. I mean the gene patent is kind
• 19:53
  Speaker 1: of a misnomer. It's a pretty big misnomer actually, because
• 19:56
  Speaker 1: there's certain criteria that have to be met. Like you,
• 20:00
  Speaker 1: you you have natural Um what is it natural matter? Um?
• 20:07
  Speaker 1: Is it is that always called? Or something of nature?
• 20:09
  Speaker 1: Composition of nature? Genes are a composition of nature in
• 20:12
  Speaker 1: your body. To patent something, you have to extract genes
• 20:14
  Speaker 1: and get them to do like, you know, jump through
• 20:16
  Speaker 1: a flaming hoop outside of the body. Then you have
• 20:20
  Speaker 1: something called composition of matter. Right. Um, So what are
• 20:24
  Speaker 1: some of the things that people are getting gene patents for? Well,
• 20:28
  Speaker 1: it breaks down, my friend, into four categories pretty much. Uh,
• 20:34
  Speaker 1: you won't go one at a time. Yeah, for a change. Diagnostics,
• 20:39
  Speaker 1: that means, uh, they're looking to patent a method. Basically
• 20:43
  Speaker 1: generally it tests for genetic differences, abnormalities, uh, spotting genetic
• 20:49
  Speaker 1: markers and cancer, alzheim or stuff like that. Right, pretty
• 20:53
  Speaker 1: nice way to use your time, I think it is.
• 20:56
  Speaker 1: But it's also very controversial. As we'll see in a
• 20:58
  Speaker 1: little bit this not all of it is, but three
• 21:01
  Speaker 1: of the four are, right. And with diagnostics, what you're
• 21:04
  Speaker 1: patenting is in fact the gene that you're looking at
• 21:08
  Speaker 1: or the genes involved, and the um the mutations. Right,
• 21:13
  Speaker 1: so you have a bunch of different possible mutations, right,
• 21:18
  Speaker 1: but a very sharp company. And by the way, by
• 21:21
  Speaker 1: saying you need to know what you're talking about or
• 21:23
  Speaker 1: you need to have put some sort of UM research
• 21:27
  Speaker 1: into this basically excluded schmos like you and I from
• 21:30
  Speaker 1: getting gene patents. And just said, huge laboratories, huge corporations
• 21:34
  Speaker 1: are the only ones who can possibly get gene patents now. Um,
• 21:37
  Speaker 1: so if you have a very sharp laboratory or very
• 21:39
  Speaker 1: sharp corporation, they're gonna have a patent for every possible
• 21:43
  Speaker 1: mutation for a specific gene and then ultimately what they're
• 21:47
  Speaker 1: patenting is the screening process. The test hit exactly used
• 21:51
  Speaker 1: to evaluate these mutations. So that's number one. UH functional
• 21:56
  Speaker 1: uses the second that is pretty much just discovering roles
• 22:00
  Speaker 1: played by genes. Uh. They're usually issued for drugs that
• 22:04
  Speaker 1: affect the functioning of the genes. Yeah, so I guess
• 22:07
  Speaker 1: insulin would be that. Uh No, insulin is composition of matter.
• 22:12
  Speaker 1: So functional, we understand that this mutation on this gene
• 22:18
  Speaker 1: causes this to happen. So we're going to create a
• 22:20
  Speaker 1: drug that makes the gene act normally, expressed normally something
• 22:25
  Speaker 1: like that, And that's the that's the future of UM
• 22:28
  Speaker 1: pharmaceuticals is genetically tailored drugs because right now, when you
• 22:33
  Speaker 1: take a drug right Thailand all or something, you're just
• 22:36
  Speaker 1: throwing something in the in the wind and hoping it works. Right,
• 22:41
  Speaker 1: genetically tailor drugs, it's like, look at your genetic composition
• 22:45
  Speaker 1: and then say, well, this is the drug you need
• 22:47
  Speaker 1: and it will work at the time and it will
• 22:50
  Speaker 1: work effectively. Dollars, please make it check out. UH process
• 22:58
  Speaker 1: is the third type of patent in this category, and
• 23:01
  Speaker 1: that's pretty easy. That's basically protecting a method by which
• 23:05
  Speaker 1: the genes are extracted or manipulated. And it's the least
• 23:08
  Speaker 1: controversial out of all these because it's not it's a
• 23:13
  Speaker 1: more traditional kind of patent, right, This is like science. Yeah,
• 23:17
  Speaker 1: and then you have composition of matter. That's yeah, composition
• 23:21
  Speaker 1: of matter and diagnostics are the two most controversial. And
• 23:24
  Speaker 1: composition of matter is like human growth hormone insulin stuff
• 23:28
  Speaker 1: that saves lives. Um and but it's an invention quote
• 23:33
  Speaker 1: unquote it is, I mean like creating human growth hormone
• 23:39
  Speaker 1: using E. Coal i to string together amino acids. That's
• 23:42
  Speaker 1: an invention and hats off to you. So what's what's
• 23:46
  Speaker 1: the controversy? What's the problem with gene patents with it's
• 23:49
  Speaker 1: issuing twenty years of exclusivity to somebody who you know,
• 23:53
  Speaker 1: teaches the coal i to string together amino acids. Well,
• 23:56
  Speaker 1: there's a couple of different controversies, one the ethical and
• 24:02
  Speaker 1: social and economic, the others the legal. As far as
• 24:04
  Speaker 1: legal goes, if you're against it, you're gonna argue that, dude,
• 24:09
  Speaker 1: these are your genes. There is nothing more natural than
• 24:13
  Speaker 1: the genes in your body, So of course you can't
• 24:15
  Speaker 1: patent them. And it doesn't matter what you do to them,
• 24:17
  Speaker 1: like it's still based on this product of nature. That
• 24:21
  Speaker 1: just leave it alone, Like this should be this, This
• 24:24
  Speaker 1: is the heritage of humankind. It's us, it's what makes
• 24:28
  Speaker 1: us us. Of course, we shouldn't be issuing patents to
• 24:31
  Speaker 1: corporations on genes, say, say the critics of gene pat
• 24:36
  Speaker 1: right proponents would say, hey, dude, if we can extract
• 24:40
  Speaker 1: this from the body and manipulate it many times to
• 24:43
  Speaker 1: the point where it's not even the same as before,
• 24:46
  Speaker 1: then of course you should be able to patent that right.
• 24:47
  Speaker 1: And and that's one of the reasons why we have
• 24:50
  Speaker 1: patents is to reward innovation, to reward very smart people,
• 24:53
  Speaker 1: and to encourage more innovation and research and things that
• 24:56
  Speaker 1: save lives, like so you don't have to extract growth
• 25:00
  Speaker 1: formon from the pituitary glance of the dead um myriad genetics.
• 25:05
  Speaker 1: Should we talk about that. It's a good example. This
• 25:06
  Speaker 1: is a big one. Uh. They filed seven patents relating
• 25:10
  Speaker 1: to h r C A one and b r C
• 25:13
  Speaker 1: A two. Basically, what they developed was a test kit
• 25:17
  Speaker 1: for breast and ovarian cancer. Right, and these these two
• 25:20
  Speaker 1: um genes account for I think, like of breast de
• 25:25
  Speaker 1: ovarian cancer, I think breast cancer. So it's pretty substantial.
• 25:29
  Speaker 1: And uh, Myriad got a patent on the screening kit
• 25:33
  Speaker 1: that they created, and they promptly turned around and sent
• 25:37
  Speaker 1: letters to just about every cancer screening laboratory in the
• 25:42
  Speaker 1: world right and said, hey, we're here that you guys
• 25:47
  Speaker 1: are saving people's lives. That's awesome. I think, keep up
• 25:49
  Speaker 1: the good work. Just make sure that you send all
• 25:51
  Speaker 1: of your cancer screening when it relates to these two
• 25:53
  Speaker 1: genes to us, and we'll do it, and we're going
• 25:55
  Speaker 1: to charge you for it. And throughout the world, people
• 25:59
  Speaker 1: in laboratories through these letters up in the air and
• 26:04
  Speaker 1: and clucked their tongues and stroked their beards and anger
• 26:07
  Speaker 1: and strutted about their flasks and and in Canada it
• 26:11
  Speaker 1: was just overtly ignored. The Canadian government itself stepped and
• 26:14
  Speaker 1: it was like, you don't need to listen to these crackpots. Um.
• 26:19
  Speaker 1: In Europe it was very controversial. I think it's largely ignored.
• 26:22
  Speaker 1: So it's upheld I think in the US because this
• 26:25
  Speaker 1: was the country that issued the patent, But elsewhere they're like,
• 26:28
  Speaker 1: we're not listening to you. And for a long time,
• 26:31
  Speaker 1: Myriad didn't do anything. There wasn't any lawsuits. Uh, and
• 26:34
  Speaker 1: then there was one, and in two thousand and ten
• 26:38
  Speaker 1: the company, um, yeah, Well the U. S. District Court said,
• 26:42
  Speaker 1: now we're not We're not going to support this. And
• 26:45
  Speaker 1: then in two thousand eleven Court of Appeal for the
• 26:47
  Speaker 1: Federal Circuit overturned that lower court's decision, so it went
• 26:51
  Speaker 1: up one step higher and Myriad got satisfaction. They got
• 26:55
  Speaker 1: Myriad satisfaction. Yeah, you know that means thirty tho. It's
• 27:00
  Speaker 1: an actual number, Myriad. Yeah, just like decimated as ten.
• 27:04
  Speaker 1: But this is one that I'm I'm on the side
• 27:07
  Speaker 1: of the people using it correctly because I can't stand
• 27:10
  Speaker 1: it when someone says like I had a myriad of yeah,
• 27:14
  Speaker 1: when it's supposed to be just myriad, I had thirty
• 27:17
  Speaker 1: thousand costs. See that's where I disagree with the thirty
• 27:21
  Speaker 1: thou part, Like, say it correctly, but come on, or
• 27:26
  Speaker 1: you could just say like I had a myriad of
• 27:28
  Speaker 1: costs and then wink afterywere like, I don't want to
• 27:30
  Speaker 1: talking about him, just pull my finger. So the Myriad
• 27:35
  Speaker 1: case continues. I did I did, like when it was
• 27:38
  Speaker 1: initially ruled against the ruling judge. He sounded really like
• 27:42
  Speaker 1: a who was Andy Griffith's judge character or no lawyer character,
• 27:47
  Speaker 1: Matt Luck it's a that's a lawyer's trick. That's what
• 27:50
  Speaker 1: he called it. And then they Supreme Court said, no,
• 27:53
  Speaker 1: it's not a trick. They modified it, your honor. I
• 27:56
  Speaker 1: don't know spit about lawyer, but do know the human heart.
• 28:01
  Speaker 1: I never saw that show. I didn't either, but there
• 28:04
  Speaker 1: was a good Senenate live send up of it. Of course,
• 28:07
  Speaker 1: still Hartman did r I P. Phil Hartman. So ethical
• 28:13
  Speaker 1: social challenges and controversies, this is where it gets hot. Yeah,
• 28:17
  Speaker 1: and I guess we should say, like we just kind
• 28:19
  Speaker 1: of left it, like myrroads up in the air. That's
• 28:22
  Speaker 1: the standard for what's going on in the US right
• 28:25
  Speaker 1: now as far as gene pattents go. And that was
• 28:26
  Speaker 1: just a few months ago. The Pattent Office is honoring
• 28:29
  Speaker 1: its obligations, and then the courts are people are suing people,
• 28:32
  Speaker 1: and the courts are just going all over the place.
• 28:35
  Speaker 1: So it's just totally up in the air whether or
• 28:38
  Speaker 1: not this is going to be allowed or what kind
• 28:41
  Speaker 1: of standards will eventually adopt the heat of this. Yeah,
• 28:44
  Speaker 1: we are so yeah, let's talk about ethical the ethics
• 28:49
  Speaker 1: of this, right yeah. I mean it's sort of along
• 28:51
  Speaker 1: the same lines in a way as the legal challenges,
• 28:54
  Speaker 1: because proponents are gonna say, you know this, this is
• 28:57
  Speaker 1: great for research. If you don't, if you don't allow this,
• 29:02
  Speaker 1: then companies aren't gonna be able to make a profit
• 29:06
  Speaker 1: from this. So there's going to be no incentive if
• 29:08
  Speaker 1: to to continue this kind of research. Reacharch is gonna stop.
• 29:11
  Speaker 1: And this research is important. Like you can say what
• 29:14
  Speaker 1: you will about Myriad, but they're screening test saves lives
• 29:19
  Speaker 1: and if they invented it, then this sort of breaks
• 29:22
  Speaker 1: down almost into private sector capitalism versus because if the
• 29:27
  Speaker 1: private sector dried up because they couldn't make any money
• 29:29
  Speaker 1: off this stuff, all the research would be left to
• 29:32
  Speaker 1: government funded laboratories. Right. It's it's very much divided among
• 29:38
  Speaker 1: capitalists socialist lines, and I think though that people who
• 29:41
  Speaker 1: normally wouldn't consider themselves socialists are falling into the critics
• 29:46
  Speaker 1: camp just from the just the idea of you know,
• 29:50
  Speaker 1: having gene patents out there. It's it is something that
• 29:53
  Speaker 1: I think a lot of people think should just belong
• 29:55
  Speaker 1: to all humankind. But the the free market proponents do
• 29:59
  Speaker 1: may a pretty good case. You know, if that if
• 30:05
  Speaker 1: you don't reward innovation and invention and clever yeah the
• 30:12
  Speaker 1: techniques monetarily, then you have a problem. On the other side, though,
• 30:17
  Speaker 1: you can say, well, you're also issuing monopolies on things
• 30:21
  Speaker 1: that like our life saving that a company can charge
• 30:24
  Speaker 1: whatever they want, Like what will you pay to find
• 30:27
  Speaker 1: out you know whether you have cancer? Or what will
• 30:31
  Speaker 1: you pay for a drug that will get rid of
• 30:34
  Speaker 1: your cancer, Chuck Bryant, Because we know your genetic makeup
• 30:39
  Speaker 1: and we know that this will work perfectly with your
• 30:41
  Speaker 1: genetic makeup. How much will you pay for that? And
• 30:44
  Speaker 1: we're the only company you can get it from. I'd
• 30:46
  Speaker 1: pay everything I had. Yes, you would know, and so
• 30:49
  Speaker 1: would you know every other person who had the same
• 30:51
  Speaker 1: similar genetic makeup as you, which is problematic. And also
• 30:56
  Speaker 1: if it if it, here's your cancer, but the three
• 31:00
  Speaker 1: weeks later your head explodes, but it doesn't happen in everybody.
• 31:04
  Speaker 1: That company has zero incentive to make its product so
• 31:08
  Speaker 1: that it doesn't make you know, the thirty percent of
• 31:11
  Speaker 1: people's heads explode because it has a monopoly. What are
• 31:14
  Speaker 1: you gonna do? You're still gonna buy this thing. Right.
• 31:17
  Speaker 1: Another argument for is that at least what this process
• 31:21
  Speaker 1: does is creates transparency and research. It's all out there.
• 31:25
  Speaker 1: Everybody knows there's people might not be wasting their time
• 31:28
  Speaker 1: duplicating research a and be uh people can build on
• 31:33
  Speaker 1: your research and it will propel it further into the future.
• 31:38
  Speaker 1: Should pretty good argument there. Yeah, but you can understand
• 31:41
  Speaker 1: why this is not a cut and dried argument. Well,
• 31:44
  Speaker 1: the A m A says we know, like, yeah, the
• 31:48
  Speaker 1: A m A saying like that this won't help support
• 31:52
  Speaker 1: research for American Medical Association. It's saying that, um, it
• 31:55
  Speaker 1: will inhibit uh research on genetic disease and basically, even
• 32:01
  Speaker 1: worse than that, it will inhibit access for the average person.
• 32:05
  Speaker 1: So I want to give an example of what is
• 32:07
  Speaker 1: at stake here. Okay, so we've kind of seen like,
• 32:11
  Speaker 1: you know, this kind of this kind of reward does
• 32:15
  Speaker 1: propel innovation and research. Right, But there's this UM with
• 32:22
  Speaker 1: the Plant Act of UM that allowed people to genetically
• 32:27
  Speaker 1: modify plants Luther Burbank, Yeah, um and then get patents
• 32:32
  Speaker 1: for those. There's a company called Monsanto and Montsano came
• 32:36
  Speaker 1: up with this idea called UM Genetic Use Restriction technology.
• 32:40
  Speaker 1: It's UM also known as terminator technology, where they have
• 32:44
  Speaker 1: figured out how to insert a gene basically a suicide
• 32:49
  Speaker 1: gene into its seeds. It's genetically modified seeds right for
• 32:54
  Speaker 1: second seeds, yes, so for the first generation seed you
• 32:59
  Speaker 1: your plant just grow like normal, like a normal genetically
• 33:03
  Speaker 1: modified organism. It will produce seeds, but those seeds it
• 33:07
  Speaker 1: produces are sterile because it has a gene in it
• 33:10
  Speaker 1: that that won't allow it to produce seeds that can
• 33:13
  Speaker 1: be used again. This means that you have to go
• 33:16
  Speaker 1: to Monsano to buy their seeds. You can't hoard their
• 33:18
  Speaker 1: seeds and replant next year. Every year you have to
• 33:21
  Speaker 1: go and buy their seeds. This is fine and dandy
• 33:24
  Speaker 1: for very wealthy farmers in the West, but no matter
• 33:27
  Speaker 1: where you are in the world, if you want to
• 33:29
  Speaker 1: grow this you know UM cricket resistant type of wheat
• 33:33
  Speaker 1: that Monsano owns a patent on, you got to buy
• 33:36
  Speaker 1: it from Monsano and you have to buy it every
• 33:37
  Speaker 1: year wheter what you can afford or can't. And basically
• 33:41
  Speaker 1: there's a really good argument that you should not be
• 33:43
  Speaker 1: allowed to to own a patent a license on a
• 33:50
  Speaker 1: process as natural as a plant producing offspring producing seeds.
• 33:56
  Speaker 1: So that's one example that a lot of people point
• 33:59
  Speaker 1: to is like cautionary tale. Well, they for against gene pattons.
• 34:04
  Speaker 1: They did not, Monsanto did not. They still hold this.
• 34:07
  Speaker 1: They didn't release it and say this is what we're doing.
• 34:09
  Speaker 1: You know, they actually vowed to not do that. Yeah,
• 34:11
  Speaker 1: they said, we won't do it, but you've got to
• 34:13
  Speaker 1: sign this agreement if you do business with us, or
• 34:16
  Speaker 1: we'll start releasing this right, And the agreement says that
• 34:19
  Speaker 1: you won't reuse seeds that you get from their genetically
• 34:23
  Speaker 1: modified plants. And didn't they buy up the company that
• 34:25
  Speaker 1: was originally ah Delta and pine Land Company. They ended
• 34:31
  Speaker 1: up buying them up, didn't they? Yes, and they they
• 34:34
  Speaker 1: this company has said has vowed the opposite that they're
• 34:37
  Speaker 1: going to start using that terminator gene commercially. Oh they have. Yeah.
• 34:44
  Speaker 1: So a lot of people are very nervous about whether
• 34:46
  Speaker 1: or not that genetic use restriction technology will come into play.
• 34:50
  Speaker 1: But I mean it's already effectively in play. We should
• 34:54
  Speaker 1: do a Monsanto podcast that would be explosive, would be
• 34:59
  Speaker 1: very explosive. We will. So that's gene pattents. This is uh,
• 35:02
  Speaker 1: we haven't done one of these in a while. I'm
• 35:04
  Speaker 1: quite sure we're gonna hear from people on both sides
• 35:06
  Speaker 1: of this issue, and we want to. Yeah, I think
• 35:09
  Speaker 1: we did a good job this time of keeping our
• 35:11
  Speaker 1: own dirty laundry out of it. Yes, we did. Kudos
• 35:14
  Speaker 1: to you, buddy. And um so if you we have
• 35:17
  Speaker 1: a bunch of stuff on Jeanes and Gene Pattents on
• 35:19
  Speaker 1: how Stuff Works dot com, just type in Gene Pattents
• 35:22
  Speaker 1: that will bring up a lot of stuff, including a
• 35:24
  Speaker 1: quiz which you could say is maybe a compendium to this,
• 35:27
  Speaker 1: uh this episode. Who wrote this one? Uh, Michael Franco,
• 35:34
  Speaker 1: I don't Yeah, he does everything does um, But yeah,
• 35:38
  Speaker 1: it was a pretty good article. But just type in
• 35:40
  Speaker 1: Gene Patton said the search bar how stuff works dot Com. Also,
• 35:42
  Speaker 1: don't forget check out the corporation. Uh, it's just a
• 35:45
  Speaker 1: really interesting documentary. Um. And I said search bar in
• 35:50
  Speaker 1: there somewhere. So that means it's time for listener mail.
• 35:52
  Speaker 1: And this is the winning listener mail, is it? It's
• 35:56
  Speaker 1: the first one? Really? Yeah, promised a book to the
• 36:03
  Speaker 1: the The author of this email will receive a free
• 36:06
  Speaker 1: copy hardcover copy of John Hodgman's incredible book about the
• 36:12
  Speaker 1: end of the world. The third in this trilogy of
• 36:16
  Speaker 1: knowledge World Knowledge called That Is All, which just came
• 36:20
  Speaker 1: out of November one hof and you really should buy it. Yeah,
• 36:24
  Speaker 1: except for this person, John's a buddy and stuff. But
• 36:26
  Speaker 1: it's a very very fun book. Um all right, I
• 36:31
  Speaker 1: kind of forgot that when I picked this, but I
• 36:35
  Speaker 1: think this Turkish listener is is uh, he deserves it,
• 36:39
  Speaker 1: so yeah, we'll go with him, The Lucky Turk, The
• 36:42
  Speaker 1: Lucky Turk. Hey, guys, listening to you from Turkey. I
• 36:45
  Speaker 1: guess I gave that away. I really love the podcast.
• 36:48
  Speaker 1: Thanks a lot for what you're doing. This might sound
• 36:50
  Speaker 1: a bit like complaining, thought wait, wait, wait, I'd prefer
• 36:55
  Speaker 1: that I don't come across this complaining. And I don't
• 36:57
  Speaker 1: know if you even have any more listeners from Turkey,
• 37:00
  Speaker 1: But in various episodes, every time you mentioned Turkey, like
• 37:03
  Speaker 1: when somebody was stuck in Turkey on the last episode
• 37:05
  Speaker 1: where you were wondering if people can surf on the
• 37:09
  Speaker 1: boss for us Phosphorus Bosporus, it always kind of sounds
• 37:12
  Speaker 1: like you look down on Turkey a bit, to be honest. Untrue.
• 37:16
  Speaker 1: Now we we talked about being stuck in Turkey and
• 37:19
  Speaker 1: how awful that would be. That's I don't recall that
• 37:21
  Speaker 1: because I would love to go to Turkey sometimes. I
• 37:24
  Speaker 1: have a friend who played bass in the second most
• 37:27
  Speaker 1: popular Turkish rock band in the late nineties. Really yeah,
• 37:33
  Speaker 1: I don't remember the name of it, but PEPSI did
• 37:35
  Speaker 1: a poll of Turks and my friend's band came in
• 37:37
  Speaker 1: second and most popular was your friend Turkish. No, he
• 37:41
  Speaker 1: went to Turkey just for the heck of it and
• 37:43
  Speaker 1: ended up in the number two most popular rock band
• 37:46
  Speaker 1: in Turkey. That's probably not hard to do. See, that's
• 37:49
  Speaker 1: what this guy's talking about. It's you, Chuck, I'm getting
• 37:52
  Speaker 1: wrapped up in your problems, al right. Sorry to drag
• 37:55
  Speaker 1: you down. You guys seem to be a couple of
• 37:58
  Speaker 1: people who would like to know the facts. So I
• 38:00
  Speaker 1: just wanted to suggest you check out things like ohlu
• 38:03
  Speaker 1: Deniz Turkey, or maybe Fethaette Turkey or Bodrum Turkey in
• 38:08
  Speaker 1: Google images. I'm just saying, I don't think anyone wouldn't
• 38:12
  Speaker 1: mind being stuck in Turkey, really, if you really know
• 38:14
  Speaker 1: what Turkey was like, and I did look these places up, dude,
• 38:18
  Speaker 1: you know, gorgeous Turkey also arguably has the world's first city.
• 38:22
  Speaker 1: I can't remember what it's called, but it's just because
• 38:26
  Speaker 1: I felt like I have to say this since I'm
• 38:27
  Speaker 1: already writing an email. There is no surfing on the Bosphorus,
• 38:30
  Speaker 1: not even swimming on the Bosphorus. It's kind of dangerous.
• 38:33
  Speaker 1: Usually it's just bigger ships crossing country that use that,
• 38:36
  Speaker 1: and there are no beaches there. But Turkey is surrounded
• 38:39
  Speaker 1: on three sides by the sea, basically a peninsula, so
• 38:43
  Speaker 1: there's windsurfing, every kind of water sport you can think
• 38:45
  Speaker 1: of on the seaside cities. Uh. In the media, Turkey
• 38:48
  Speaker 1: comes across as if it was a dusty hut and
• 38:51
  Speaker 1: primitive country, which I think is what I had been saying,
• 38:55
  Speaker 1: and I should say. When I worked for my last company,
• 38:58
  Speaker 1: which was a chicken software company, one of our clients
• 39:00
  Speaker 1: was in Turkey and some of our guys would go
• 39:03
  Speaker 1: over there to the chicken farms and it was awful too.
• 39:07
  Speaker 1: They would come back saying, please God, don't ever send
• 39:10
  Speaker 1: me to Turkey again. They were in like the awful
• 39:13
  Speaker 1: part of Turkey. They were raising chickens and Turkey. Yeah, yeah,
• 39:18
  Speaker 1: I have to say that, though only some small cities
• 39:20
  Speaker 1: on the eastern edges are like that, guys. The people
• 39:22
  Speaker 1: in different clothes are more interesting than people to look
• 39:26
  Speaker 1: at who look like most of us, who look like
• 39:29
  Speaker 1: every other European country. So the media only reflects the
• 39:33
  Speaker 1: different part, kind of like only showing rednecks grilling steak
• 39:36
  Speaker 1: on a shopping cart I've never seen. I guess I'm
• 39:41
  Speaker 1: gonna the rest of Turkeys pretty much like California, great climate, people,
• 39:46
  Speaker 1: social and cultural, culturally, even especially Istanbul, it resembles a
• 39:51
  Speaker 1: very crowded San Francisco, not Constantinople, what with all the
• 39:54
  Speaker 1: hills and the bridges and the hipsters. So that is
• 39:57
  Speaker 1: from goes to ge z d E And dude, you're
• 40:03
  Speaker 1: getting a book. And I am sorry for bad mouthing
• 40:06
  Speaker 1: Turkey because I did look at pictures and it's nothing
• 40:08
  Speaker 1: at all like I thought. I'm not sorry for bad
• 40:11
  Speaker 1: mouthing Turkey because I didn't. I didn't and if I did,
• 40:14
  Speaker 1: I was totally joking. Then I feel like I owe
• 40:17
  Speaker 1: this guy book. Yeah, the only place in the world
• 40:19
  Speaker 1: I would never go is Detroit. I totally go to Turkey.
• 40:23
  Speaker 1: Detroit's awesome. So what's the name goest you get a book?
• 40:26
  Speaker 1: So you're gonna have to write back in Yeah, we
• 40:28
  Speaker 1: need your mailing address, goest to, and we should probably
• 40:32
  Speaker 1: make them, you know, pay the difference for international shipping. Well,
• 40:35
  Speaker 1: and it's Turkey. It probably just says goes to Turkey.
• 40:37
  Speaker 1: That's his name, because we'll just put a bunch of
• 40:42
  Speaker 1: stamps on it and throw it in the water exactly. Uh.
• 40:45
  Speaker 1: Goest to send us an email with your mailing address, UM,
• 40:48
  Speaker 1: because we really think there probably are more than one
• 40:50
  Speaker 1: of you in Turkey. Uh and uh to all the
• 40:54
  Speaker 1: rest of you. If we send an emails, UM, thank you.
• 40:57
  Speaker 1: We'll try to read them, but you get no books.
• 41:00
  Speaker 1: If you want to get in touch with us, you
• 41:01
  Speaker 1: can on Twitter, s y SK podcast, on Facebook, Facebook
• 41:04
  Speaker 1: dot com, slash stuff you Should Know, and via email
• 41:08
  Speaker 1: at stuff Podcast at how Stuff works dot com. Be
• 41:19
  Speaker 1: sure to check out our new video podcast, Stuff from
• 41:22
  Speaker 1: the Future. Join how Stuff Work staff as we explore
• 41:25
  Speaker 1: the most promising and perplexing possibilities of tomorrow, brought to
• 41:31
  Speaker 1: you by the reinvented two thousand twelve camera. It's ready,
• 41:34
  Speaker 1: are you